10-KPeriod: FY2022

AMGEN INC Annual Report, Year Ended Dec 31, 2022

Filed February 9, 2023For Securities:AMGN

Summary

Amgen Inc. (AMGN) presented its 2022 annual report, highlighting robust product sales growth, particularly driven by Prolia, Repatha, and EVENITY. The company's total product sales increased by 2% to $24.8 billion, despite challenges like biosimilar competition and pricing pressures. A significant strategic move during the year was the announcement of the proposed acquisition of Horizon Therapeutics for approximately $27.8 billion, signaling Amgen's intent to expand its portfolio into rare, autoimmune, and inflammatory diseases. The company also advanced its pipeline, initiating Phase 3 trials for several key programs, including LUMAKRAS/LUMYKRAS for colorectal cancer and olpasiran for cardiovascular disease. Amgen continues to focus on innovation, manufacturing advancements, and global expansion, while navigating a complex regulatory and reimbursement landscape. The company maintained a strong financial position, with significant cash flow from operations and ongoing capital returns to shareholders through dividends and stock repurchases, though it also faces ongoing litigation regarding tax matters with the IRS.

Financial Highlights

56 data points
Beta

Revenue

$26.32B

75.7% Gross Margin

Net Income

$6.55B

24.9% Net Margin

EPS (Diluted)

$12.11

Total Assets

$65.12B

Cash & Equivalents

$7.63B

Free Cash Flow

$8.79B

Financial Statements
Beta
Revenue$26.32B
Cost of Revenue$6.41B
Gross Profit$19.92B
SG&A Expenses$5.41B
Operating Expenses$16.76B
Operating Income$9.57B
Interest Expense$1.41B
Net Income$6.55B
EPS (Basic)$12.18
EPS (Diluted)$12.11
Shares Outstanding (Basic)538.00M
Shares Outstanding (Diluted)541.00M

Key Highlights

  • 1Amgen announced a proposed $27.8 billion acquisition of Horizon Therapeutics to expand its presence in rare and autoimmune diseases.
  • 2Total product sales grew 2% to $24.8 billion, driven by volume increases in key products like Prolia, Repatha, and EVENITY.
  • 3The company initiated Phase 3 clinical trials for several pipeline candidates, including LUMAKRAS/LUMYKRAS (colorectal cancer) and olpasiran (cardiovascular disease).
  • 4Amgen acquired ChemoCentryx for approximately $3.8 billion, adding TAVNEOS to its inflammation portfolio.
  • 5Despite biosimilar competition impacting products like Neulasta (sales down 35%), Amgen is also advancing its own biosimilar portfolio.
  • 6The company continues to invest heavily in R&D, with expenses totaling $4.4 billion, supporting a pipeline with 18 Phase 3 programs.
  • 7Amgen returned significant capital to shareholders in 2022, repurchasing $6.3 billion in stock and increasing its quarterly dividend by 10%.

Frequently Asked Questions

Amgen's key growth drivers in 2022 were volume increases in products like Prolia, Repatha, and EVENITY, contributing to a 2% rise in total product sales to $24.8 billion. However, the company faces challenges including increasing competition from biosimilars and generics, which significantly impacted sales of products like Neulasta (down 35%), and ongoing pricing and reimbursement pressures from payers.

The proposed acquisition of Horizon Therapeutics for $27.8 billion is a major strategic move for Amgen, aimed at significantly expanding its portfolio in rare, autoimmune, and severe inflammatory diseases. Horizon Therapeutics brings a pipeline of over 20 development programs and 12 marketed medicines, offering substantial growth potential and diversification for Amgen.

Amgen is actively advancing its product pipeline, notably initiating Phase 3 trials for multiple candidates, including LUMAKRAS/LUMYKRAS for advanced colorectal cancer and olpasiran for cardiovascular disease. R&D expenses totaled $4.4 billion in 2022, supporting a robust pipeline with 18 Phase 3 programs. The company also complements internal R&D through strategic acquisitions, such as ChemoCentryx, to bolster its therapeutic areas.

Amgen maintains a strong financial position with $9.3 billion in cash, cash equivalents, and marketable securities as of December 31, 2022. The company generated $9.7 billion in cash flow from operations and returned capital to shareholders through $6.3 billion in stock repurchases and a 10% increase in its quarterly dividend. Amgen's capital allocation strategy includes investing in innovation, strategic transactions, debt repayment, and shareholder returns.